Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 142

Similar articles for PubMed (Select 23754241)

1.

Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?

Besada E, Nossent JC.

Clin Rheumatol. 2013 Nov;32(11):1677-81. doi: 10.1007/s10067-013-2293-4. Epub 2013 Jun 11.

PMID:
23754241
2.

[Pneumocystis jiroveci infection in patients with and without HIV: A comparison].

Rey A, Losada C, Santillán J, Fiorentini F, Schiaffino M, Peroni HJ, Giunta D, Barcán L, Waisman G.

Rev Chilena Infectol. 2015 Apr;32(2):175-80. doi: 10.4067/S0716-10182015000300006. Spanish. No abstract available.

3.

[ANCA vasculitis: Is it time to change the standard of care for maintenance?]

Guillevin L, Terrier B.

Rev Med Interne. 2015 Jun 5. pii: S0248-8663(15)00508-1. doi: 10.1016/j.revmed.2015.05.009. [Epub ahead of print] French. No abstract available.

PMID:
26055037
4.

[Rituximab (MabThera): a new therapy for ANCA vasculitis].

von Frenckell C, Delanaye P.

Rev Med Liege. 2015 Feb;70(2):92-100. French.

PMID:
26011994
5.

Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?

Kronbichler A, Jayne DR.

Nephrol Dial Transplant. 2015 Jul;30(7):1075-81. doi: 10.1093/ndt/gfv216. Epub 2015 May 21.

PMID:
25999374
6.

[Use of rituximab in the induction of remission of severe, resistant and recurrent form of polyangiitis associated with c-ANCA antibodies - case report].

Brodowska-Kania D, Rymarz A, Saracyn M, Geisler P, Niemczyk S.

Pol Merkur Lekarski. 2015 Apr;38(226):216-8. Polish.

PMID:
25938389
7.

Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.

Bunch DO, Mendoza CE, Aybar LT, Kotzen ES, Colby KR, Hu Y, Hogan SL, Poulton CJ, Schmitz JL, Falk RJ, Nachman PH, Pendergraft WF, McGregor JG.

Ann Rheum Dis. 2015 Apr 30. pii: annrheumdis-2014-206756. doi: 10.1136/annrheumdis-2014-206756. [Epub ahead of print] No abstract available.

PMID:
25934841
8.

Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis.

Jiang X, Mei X, Feng D, Wang X.

PLoS One. 2015 Apr 24;10(4):e0122171. doi: 10.1371/journal.pone.0122171. eCollection 2015.

9.

Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.

Md Yusof MY, Vital EM, Das S, Dass S, Arumugakani G, Savic S, Rawstron AC, Emery P.

Ann Rheum Dis. 2015 Apr 8. pii: annrheumdis-2014-206496. doi: 10.1136/annrheumdis-2014-206496. [Epub ahead of print]

PMID:
25854586
10.

[B cell therapy of rheumatoid arthritis with rituximab. Practice-relevant aspects for the routine].

Schmalzing M, Tony HP.

Z Rheumatol. 2015 Apr;74(3):250-7. doi: 10.1007/s00393-014-1563-0. German.

PMID:
25854158
11.

Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function.

McGregor JG, Negrete-Lopez R, Poulton CJ, Kidd JM, Katsanos SL, Goetz L, Hu Y, Nachman PH, Falk RJ, Hogan SL.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i171-81. doi: 10.1093/ndt/gfv045.

PMID:
25805747
12.

Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.

McGregor JG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez R, Kidd JM, Katsanos SL, Bunch DO, Nachman PH, Falk RJ.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i123-31. doi: 10.1093/ndt/gfv076.

PMID:
25805743
13.

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh M, Westman K, Jayne DR; European Vasculitis Society (EUVAS).

Ann Rheum Dis. 2015 Jun;74(6):1178-82. doi: 10.1136/annrheumdis-2014-206404. Epub 2015 Mar 4.

PMID:
25739829
15.

Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.

Kronbichler A, Jayne DR, Mayer G.

Eur J Clin Invest. 2015 Mar;45(3):346-68. doi: 10.1111/eci.12410.

PMID:
25627555
16.

Rituximab or azathioprine maintenance in ANCA-associated vasculitis.

Chouchana L, Beaune P, Loriot MA.

N Engl J Med. 2015 Jan 22;372(4):386. doi: 10.1056/NEJMc1414728#SA3. No abstract available.

PMID:
25607436
17.

Rituximab or azathioprine maintenance in ANCA-associated vasculitis.

Vandergheynst F.

N Engl J Med. 2015 Jan 22;372(4):385-6. doi: 10.1056/NEJMc1414728#SA2. No abstract available.

PMID:
25607435
18.

Rituximab or azathioprine maintenance in ANCA-associated vasculitis.

Hebert LA, Alvarado A, Rovin B.

N Engl J Med. 2015 Jan 22;372(4):385. doi: 10.1056/NEJMc1414728#SA1. No abstract available.

PMID:
25607434
19.

Rituximab or azathioprine maintenance in ANCA-associated vasculitis.

Pagnoux C, Guillevin L; French Vasculitis Study Group; MAINRITSAN investigators.

N Engl J Med. 2015 Jan 22;372(4):386-7. doi: 10.1056/NEJMc1414728. No abstract available.

20.

Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.

Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR.

J Autoimmun. 2015 Feb;57:24-9. doi: 10.1016/j.jaut.2014.11.004. Epub 2015 Jan 10.

PMID:
25586449
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk